Goodsurance
ES

Drug prices & Part D

Prescription Drug Prices Posted Their Steepest Annual Drop in Decades, but Reconciliation Law Exemptions Could Cost Some Medicare Enrollees Thousands

The Consumer Price Index showed drug prices fell 3.1 percent year-over-year, the biggest drop since 1963, while the Medicare Rights Center warns that exemptions added by the 2025 reconciliation law could raise Medicare costs by nearly 4 billion dollars and leave some enrollees spending roughly 3,000 dollars more per year.

By the Goodsurance editorial teamAugust 22, 2026

Prescription drug prices fell 3.1 percent from a year earlier according to the latest Consumer Price Index, the largest year-over-year decline since 1963. A Medicare Rights Center analysis published August 20, 2026 credited a combination of factors: the arrival of lower-cost generic and biosimilar products for high-cost medicines and the drug price negotiation authority that Congress granted to Medicare under the Inflation Reduction Act.

Negotiated prices for the first ten Medicare Part D drugs took effect in 2026, reaching roughly nine million beneficiaries who use those medicines for conditions including heart disease and diabetes.

Drug prices just posted a 60-year record decline, but new reconciliation law exemptions could cost some Medicare enrollees thousands more a year.

The Medicare Rights Center cautioned that the favorable headline does not tell the full story for Medicare enrollees. Exemptions added by the 2025 reconciliation law, commonly known as the One Big Beautiful Bill Act, expand which drugs are shielded from Medicare's price negotiation rules. Those exemptions are expected to raise Medicare's drug costs by nearly 4 billion dollars. Beneficiaries who rely on newly exempted medicines could face spending roughly 3,000 dollars more per year, the Medicare Rights Center said.

The analysis highlights two simultaneous trends in Medicare drug pricing: market competition and IRA-era tools are producing real savings in some areas, while recent legislative decisions have narrowed where those tools will apply going forward.

In plain words

Drug prices fell about 3 percent compared to last year. That is the biggest drop in about 60 years. Cheaper drug options and Medicare's new power to negotiate prices helped. But a big law passed in 2025 lets some drug companies skip those price talks. Because of that, some Medicare enrollees could pay around 3,000 dollars more each year for the medicines those companies make.

Source: Medicare Rights Center
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

November 16, 2026

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026